

Tibsovo® (ivosidenib) – New indication

- On August 27, 2021, <u>Servier Pharmaceuticals announced</u> the FDA approval of <u>Tibsovo (ivosidenib)</u>, for the treatment of adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDAapproved test.
- Tibsovo is also approved for newly-diagnosed acute myeloid leukemia (AML) and relapsed or refractory AML.
- The approval of Tibsovo for the new indication was based on a randomized, double-blind, placebocontrolled study in 185 adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation. Patients were randomized to receive either Tibsovo or placebo until disease progression or unacceptable toxicity. The major efficacy measure was progression free survival (PFS).
 - Progressive disease or death occurred in 61% of patients treated with Tibsovo vs. 82% with placebo (hazard ratio [HR] 0.37, 95% CI 0.25, 0.54; p < 0.0001).
 - The median overall survival (OS) for Tibsovo was 10.3 months vs. 7.5 months for placebo (HR 0.79, 95% CI: 0.56, 1.12; p = 0.093).
- Tibsovo carries a boxed warning for differentiation syndrome in AML.
- The most common adverse reactions (≥ 15%) with Tibsovo use in cholangiocarcinoma were fatigue, nausea, abdominal pain, diarrhea, cough, decreased appetite, ascites, vomiting, anemia, and rash.
- The most common laboratory abnormalities (≥ 10%) with Tibsovo use in cholangiocarcinoma were decreased hemoglobin, increased aspartate aminotransferase, and increased bilirubin.
- The recommended dose of Tibsovo is 500 mg taken orally once daily until disease progression or unacceptable toxicity.
 - Patients should be selected for the treatment of locally advanced or metastatic cholangiocarcinoma with Tibsovo based on the presence of IDH1 mutations. Information on FDA-approved tests for the detection of IDH1 mutations is available at http://www.fda.gov/CompanionDiagnostics.
 - Consult the Tibsovo drug label for dosing recommendations for AML.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.